Related Articles
Interleukin-6 is a highly prognostic biomarker for POEMS syndrome – PubMed
Interleukin-6 is a highly prognostic biomarker for POEMS syndrome
Trends in the disease burden of early-onset cancers in China from 1990 to 2021: a systematic analysis of the 2021 Global Burden of Disease study – PubMed
The mortality and DALY rate of early-onset cancers in China decreased, while the incidence rate increased. Trachea/bronchus/lung cancer is one of the most severe early-onset…
Sequential BCMA CAR-T Cell Therapy in Refractory Multiple Myeloma – PubMed
Multiple myeloma (MM) relapsing after BCMA-directed chimeric antigen receptor T-cell (CAR-T) treatment remains a therapeutic challenge. Data on re-exposure to CAR-T targeting the same antigen…
Myeloma Paper of the Day, July 12th, Suggested by Robert Orlowski – OncoDaily
Myeloma Paper of the Day, July 12th, Suggested by Robert Orlowski / Allan Motyer, Amanda Light, cancer, Casey J.A. Anttila, Daniela Amann-Zalcenstein, Edwin D
Profiling the spatial architecture of multiple myeloma in human bone marrow trephine biopsy specimens with spatial transcriptomics – PubMed
The bone marrow microenvironment is intimately linked to the biology that underpins the development and progression of multiple myeloma. However, the complex cellular and molecular…
Boosting CAR T-Cell Efficacy by Blocking Proteasomal Degradation of Membrane Antigens – PubMed
Chimeric antigen receptor (CAR) T cells exhibit high response rates in B cell malignancies, but most patients eventually relapse. A key mechanism of treatment failure…
Real-World Experience with Teclistamab for Relapsed/ Refractory Multiple Myeloma from the U.S. Myeloma Immunotherapy Consortium – PubMed
Teclistamab is an anti-CD3xBCMA bispecific antibody approved for use in relapsed/refractory multiple myeloma (MM). We undertook a retrospective study of post-approval, real-world outcomes with teclistamab…
Second Primary Malignancies and Disease Transformation in Patients With Symptomatic Waldenström’s Macroglobulinemia – PubMed
Data from our prospectively maintained multicenter database revealed that 8.6% and 3.4% of symptomatic patients with WM developed a SPM and disease transformation, respectively, over…
From CyBorD to Dara-CyBorD: ASCT Utilization Trends in AL Amyloidosis, A 15-Year Analysis – PubMed
This retrospective analysis examined 15 years of autologous stem cell transplantation (ASCT) for AL amyloidosis at Mayo Clinic (2010-2024). We aimed to assess ASCT utilization…